<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC6968813\results\search\disease\results.xml">
  <result pre="AIDS (Auckl)HIVhivHIV/AIDS (Auckland, N.Z.)1179-1373Dove 193059 doi: 10.2147/HIV.S193059 : Review Drug-Resistant" exact="Tuberculosis" post="and HIV Infection: Current Perspectives Singh et al Singh"/>
  <result pre="Perspectives Singh et al Singh et al SinghAbhijeet1http://orcid.org/0000-0001-9425-5423PrasadRajendra12BalasubramanianViswesvaran1GuptaNikhil3[1], Department of" exact="Pulmonary" post="Medicine, Vallabhbhai Patel Chest Institute, University of DelhiNew Delhi,"/>
  <result pre="Patel Chest Institute, University of DelhiNew Delhi, Delhi110007India[2], Department of" exact="Pulmonary" post="Medicine, King George Medical UniversityLucknowUttar Pradesh226003India[3], Department of Internal"/>
  <result pre="Institute of Medical SciencesLucknowUttar Pradesh226010India Correspondence: Rajendra Prasad Department of" exact="Pulmonary" post="Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, New"/>
  <result pre="4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Abstract Abstract Drug-resistant" exact="tuberculosis" post="(DR-TB), including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB"/>
  <result pre="people living with HIV. Keywords drugï»¿-resistant HIV multidrugï»¿-resistant extensively drugï»¿-resistant" exact="tuberculosis" post="fig-count: table-count: ref-count: page-count: Introduction Drug-resistant tuberculosis (DR-TB) is"/>
  <result pre="multidrugï»¿-resistant extensively drugï»¿-resistant tuberculosis fig-count: table-count: ref-count: page-count: Introduction Drug-resistant" exact="tuberculosis" post="(DR-TB) is defined as a case of TB excreting"/>
  <result pre="and XDR-TB. The last two are important forms of DR-TB." exact="MDR-TB" post="is defined as a case of TB showing either"/>
  <result pre="drugs (SLIDs), in addition to multidrug resistance. A subset of" exact="MDR-TB" post="patients may have additional resistance to second-line anti-TB drugs"/>
  <result pre="(Am)] but not to both â€&quot; also known as pre-XDR-TB." exact="MDR-TB" post="and XDR-TB are considered a global health problem with"/>
  <result pre="and challenging treatment.2 A dynamic interaction exists between TB and" exact="HIV infection." post="TB accelerates the progression of disease in people living"/>
  <result pre="between TB and HIV infection. TB accelerates the progression of" exact="disease" post="in people living with HIV (PLHIV), and PLHIV have"/>
  <result pre="in people living with HIV (PLHIV), and PLHIV have increased" exact="susceptibility to" post="TB infection. TB is a major cause of mortality"/>
  <result pre="cases. Among 30 high-burden countries with TB and HIV coinfection," exact="HIV infection" post="has been detected in 70% of patients with TB."/>
  <result pre="Among 30 high-burden countries with TB and HIV coinfection, HIV" exact="infection" post="has been detected in 70% of patients with TB."/>
  <result pre="Mozambique (58,000). Also, in 2018 0.25 million (16.8%) of a" exact="total" post="1.5 million deaths from TB showed HIV coinfection.5 Of"/>
  <result pre="associated with HIV.6 The reasons suggested are rapid progression of" exact="disease" post="due to harboring of DR strains, particularly in the"/>
  <result pre="to drug resistance and treatment failure; early reactivation of an" exact="infection" post="due to increased vulnerability in an immunocompromised state acquired"/>
  <result pre="an infection due to increased vulnerability in an immunocompromised state" exact="acquired" post="from community or institutional transmission; direct contact with DR-TB"/>
  <result pre="community or institutional transmission; direct contact with DR-TB cases, suggesting" exact="primary" post="or transmitted resistance; confounding by common risk factors, such"/>
  <result pre="transmitted resistance; confounding by common risk factors, such as intravenous" exact="drug abuse," post="imprisonment, low socioeconomic status, alcoholism, and frequent hospitalization; repeated"/>
  <result pre="DR-TB and HIV coinfection has not been exactly defined. The" exact="primary" post="reason for the lack of data is that HIV"/>
  <result pre="The primary reason for the lack of data is that" exact="HIV infection" post="and anti-TB drug-susceptibility testing (DST) are not adequately accessible"/>
  <result pre="primary reason for the lack of data is that HIV" exact="infection" post="and anti-TB drug-susceptibility testing (DST) are not adequately accessible"/>
  <result pre="and analysis of data. In the fourth WHOâ€&quot;International Union Against" exact="Tuberculosis" post="and Lung Disease global drug-surveillance report, 24 countries reported"/>
  <result pre="data. In the fourth WHOâ€&quot;International Union Against Tuberculosis and Lung" exact="Disease" post="global drug-surveillance report, 24 countries reported data on MDR-TB"/>
  <result pre="Lung Disease global drug-surveillance report, 24 countries reported data on" exact="MDR-TB" post="stratified by HIV status.7 Only eleven countries, the majority"/>
  <result pre="status.7 Only eleven countries, the majority from Eastern European and" exact="Central" post="Asian regions, reported strong associations between HIV and drug"/>
  <result pre="strong associations between HIV and drug resistance. There was a" exact="lower" post="association for DR-TB infection in PLHIV from the US."/>
  <result pre="and drug resistance. There was a lower association for DR-TB" exact="infection" post="in PLHIV from the US. Additional information on overlapping"/>
  <result pre="high-risk groups, even in countries showing a high prevalence of" exact="MDR-TB" post="along with an emerging HIV epidemic. Detailed analysis of"/>
  <result pre="the burden of TB and HIV coinfection.8 The prevalence of" exact="MDR-TB" post="was 20% higher in HIV-positive patients than HIV-negative ones."/>
  <result pre="HIV coinfection.8 The prevalence of MDR-TB was 20% higher in" exact="HIV-positive" post="patients than HIV-negative ones. HIV was not an independent"/>
  <result pre="young adult, urban residence, homelessness, and history of incarceration and" exact="drug abuse" post="were largely overlapping. The last two subgroups were at"/>
  <result pre="last two subgroups were at particular risk of HIV and" exact="MDR-TB" post="coinfection. Enhanced efforts are necessary to provide care to"/>
  <result pre="Further, a systematic review and meta-analysis has recently reported that" exact="HIV-positive" post="cases have a 24% higher risk of MDR-TB compared"/>
  <result pre="reported that HIV-positive cases have a 24% higher risk of" exact="MDR-TB" post="compared to HIV-negative ones.9 Another study observed no significant"/>
  <result pre="to HIV-negative ones.9 Another study observed no significant association between" exact="MDR-TB" post="and HIV coinfection.6 Institution-based studies have shown a stronger"/>
  <result pre="association than community- or population-based studies. With high prevalence of" exact="HIV seropositivity" post="and M/XDR-TB, countries from sub-Saharan African and Asia-Pacific regions"/>
  <result pre="high prevalence of HIV seropositivity and M/XDR-TB, countries from sub-Saharan" exact="African" post="and Asia-Pacific regions have reported very low prevalence of"/>
  <result pre="responsible for underestimation of prevalence were delay in diagnosis, increased" exact="susceptibility to" post="infection or progression of disease, and lack of infrastructure."/>
  <result pre="underestimation of prevalence were delay in diagnosis, increased susceptibility to" exact="infection" post="or progression of disease, and lack of infrastructure. The"/>
  <result pre="The WHO has projected 14 countries for high burden for" exact="MDR-TB" post="and HIV coinfection. These are Angola, China, the Democratic"/>
  <result pre="but also converged in a deadly syndemic, particularly in sub-Saharan" exact="African" post="and Eastern European regions, over the last decade, leading"/>
  <result pre="to poor treatment outcomes and high mortality.29â€&quot;31 The epidemic of" exact="HIV infection" post="in the European region is concentrated within high-risk groups,"/>
  <result pre="poor treatment outcomes and high mortality.29â€&quot;31 The epidemic of HIV" exact="infection" post="in the European region is concentrated within high-risk groups,"/>
  <result pre="is concentrated within high-risk groups, whereas that in the sub-Saharan" exact="African" post="region has affected the general population.32 Outbreaks of MDR-TB"/>
  <result pre="sub-Saharan African region has affected the general population.32 Outbreaks of" exact="MDR-TB" post="among HIV-infected patients between 1985 and 1993 have been"/>
  <result pre="that HIV epidemics facilitate TB outbreaks only by enhancing increased" exact="susceptibility to" post="infections, but that HIV coinfection was not a direct"/>
  <result pre="driver for evolution and transmission of DR strains.37 Development of" exact="acquired" post="drug resistance is of concern, due to poor compliance"/>
  <result pre="care or guidelines, causing faulty practices. Other factors responsible for" exact="acquired" post="drug resistance are suboptimal anti-TB treatment due to poor"/>
  <result pre="these factors remain common in people living with or without" exact="HIV infection." post="Primary or transmitted resistance is also responsible for epidemics"/>
  <result pre="remain common in people living with or without HIV infection." exact="Primary" post="or transmitted resistance is also responsible for epidemics or"/>
  <result pre="patients, due to either increased hospitalization in settings with poor" exact="infection" post="control or association with colleagues with M/XDR-TB, particularly in"/>
  <result pre="with restriction fragmentâ€&quot;length polymorphism among TB patients and clustering of" exact="MDR-TB" post="cases observed among HIV patients.33 Spread of drug resistance"/>
  <result pre="Ferry of the KwaZulu-Natal region in South Africa in an" exact="HIV-positive" post="population, characterized by a high mortality rate of 99%."/>
  <result pre="from Mumbai, India reported an alarmingly high burden of MDR-TB," exact="MDR-TB" post="with additional resistance to FQs or SLIDs, and XDR-TB,"/>
  <result pre="were 21% and 12%, respectively. Further, the prevalence rate of" exact="MDR-TB" post="was 11.4% among new TB cases and 36.4% among"/>
  <result pre="people is more difficult and may be confused with other" exact="pulmonary" post="or systemic infections. The clinical features, such as cough,"/>
  <result pre="more difficult and may be confused with other pulmonary or" exact="systemic" post="infections. The clinical features, such as cough, fever, night"/>
  <result pre="be extrapulmonary or atypical, such as middle- or lower-lobe infiltrates," exact="pleural" post="effusion, mediastinal lymphadenopathy, or interstitial nodular opacities, especially as"/>
  <result pre="middle- or lower-lobe infiltrates, pleural effusion, mediastinal lymphadenopathy, or interstitial" exact="nodular" post="opacities, especially as immunosuppression advances (CD4 &amp;lt;200/cm3).46 However, cavitation"/>
  <result pre="in advanced disease. Sputum-smear examination is usually positive in early" exact="disease" post="and negative in advanced disease, but contrary results can"/>
  <result pre="the aim of enhancing diagnostic yield in PLHIV with smear-negative" exact="pulmonary" post="and extrapulmonary TB.48 Clinical criteria should be initially used"/>
  <result pre="culture as the gold standard.49 For patients with advanced HIV" exact="disease" post="with extrapulmonary involvement, mycobacterial culture of other fluids (eg,"/>
  <result pre="with extrapulmonary involvement, mycobacterial culture of other fluids (eg, blood," exact="pleural" post="fluid, ascitic fluid, cerebrospinal fluid, and bone-marrow aspirates) and"/>
  <result pre="may also choose to use targeted DST for those with" exact="lower" post="CD4 counts (&amp;lt;200 cells/mm3), as these patients are at"/>
  <result pre="The CBNAAT can establish diagnoses in smear-positive and even smear-negative" exact="pulmonary" post="TB and extrapulmonary TB, decreasing the time a patient"/>
  <result pre="Z, FQs, and SLIDs, with rapid turnover of 1â€&quot;2 days." exact="Resistance" post="can be detected by WGS for even bedaquiline (Bdq)"/>
  <result pre="high burden of disease.55 This could be attributed to the" exact="limited" post="genomic database of ongoing transmission of TB among PLHIV."/>
  <result pre="to improve treatment outcomes of MDRâ€‘TB.1,51,58 The currently recommended shorter" exact="MDR-TB" post="regimen consists of an intensive phase of 4 months"/>
  <result pre="the center, and such conditions as pregnancy, disseminated, meningeal, or" exact="central nervous system" post="TB. Anti-TB drugs have been reclassified by the WHO"/>
  <result pre="of SLIDs, such as Km or Cm, and preference for" exact="complete" post="oral drugs is recommended for designing a regimen to"/>
  <result pre="shorter regimens be used as the first preference in eligible" exact="MDR-TB" post="cases with or without HIV coinfection, otherwise all oral"/>
  <result pre="outcomes. These trials are conducted by Research Excellence to Stop" exact="Tuberculosis" post="Resistance, which is an initiative adopted under the End"/>
  <result pre="antitubercular drugs for design of regimens for treatment of drug-resistant" exact="tuberculosis" post="WHO Guidelines 201456 WHO Guidelines 201651 WHO Guidelines 20191"/>
  <result pre="core second-line agents EtoPtoCsTrdLzdCfz Group CAddition of these drugs to" exact="complete" post="regimen when drugs from abovementioned groups cannot be used"/>
  <result pre="H Group 5Drugs with unclear efficacy or unclear role in" exact="MDR-TB" post="treatment, not recommended by WHO for routine use in"/>
  <result pre="MDR-TB treatment, not recommended by WHO for routine use in" exact="MDR-TB" post="patients BdqDlmLzdCfzAmx-ClvIpm-ClnMpmHigh-dose HTClr D2BdqDlm D3PASIpm-ClnMpmAmx-ClvT Abbreviations: H, isoniazid; R,"/>
  <result pre="If first-line regimen contains Efv or Nvp: Lpv/r or Atv/r" exact="MDR-TB" post="with additional FQ resistance (pre-XDR-TB) IP (6â€&quot;9 months): Mfx"/>
  <result pre="are indicated when there is resistance or intolerance to NRTIs." exact="Failure" post="of first-line ART followed by switching to second- or"/>
  <result pre="by switching to second- or third-line ART is assessed by" exact="viral" post="load testing, documentation of exposure history to drugs, enhanced"/>
  <result pre="has a propensity to cause skin rash and immunoreconstitution inflammatory" exact="syndrome" post="(IRIS), which might complicate the therapy. Initiating ART Treatment"/>
  <result pre="2 weeks of initiating TB treatment when there is advanced" exact="disease" post="with CD4 count &amp;lt;50/cm3. This is also applicable for"/>
  <result pre="between antiretroviral and antitubercular drugs Enzyme Antitubercular drugs Antiretroviral drugs" exact="Hepatic" post="5Ê¹ glucuronidation Azt; Abc CYP1A2 R (inducer); H (inhibitor);"/>
  <result pre="ADRs to both anti-TB and other non-TB medications for other" exact="opportunistic infections," post="and the risk of ADRs increases with the degree"/>
  <result pre="intense monitoring, as there is potential for significant worsening of" exact="peripheral neuropathy" post="associated primarily with either HIV infection or combination with"/>
  <result pre="monitoring, as there is potential for significant worsening of peripheral" exact="neuropathy" post="associated primarily with either HIV infection or combination with"/>
  <result pre="for significant worsening of peripheral neuropathy associated primarily with either" exact="HIV infection" post="or combination with stavudine (d4T) and also bone-marrow depression"/>
  <result pre="significant worsening of peripheral neuropathy associated primarily with either HIV" exact="infection" post="or combination with stavudine (d4T) and also bone-marrow depression"/>
  <result pre="HIV infection or combination with stavudine (d4T) and also bone-marrow" exact="depression" post="when coadministered with Azt. Active TB drug-safety monitoring and"/>
  <result pre="to antiretroviral and antitubercular drugs Toxicity Antiretroviral Antitubercular Comments Peripheral" exact="neuropathy" post="D4T, ddI, ddC Lzd, Cs, H, Sm, Km, Am,"/>
  <result pre="ddC in combination with Cs or Lzd because of increased" exact="peripheral" post="neuropathyâ—� If these agents must be used and peripheral"/>
  <result pre="increased peripheral neuropathyâ—� If these agents must be used and" exact="peripheral neuropathy" post="develops, replace the ART with a less neurotoxic agent"/>
  <result pre="peripheral neuropathyâ—� If these agents must be used and peripheral" exact="neuropathy" post="develops, replace the ART with a less neurotoxic agent"/>
  <result pre="neuropathy develops, replace the ART with a less neurotoxic agent" exact="Central" post="nervous system (CNS) toxicity Efv Cs, H, Eto/Pto,Ofx, Lfx,"/>
  <result pre="Depression/psychosis Efv Cs, Tzd, Ofx, Lfx, Mfx, H, Eto/Pto â—�" exact="Severe" post="depression can be seen in 2.4% of patients receiving"/>
  <result pre="Efv Cs, Tzd, Ofx, Lfx, Mfx, H, Eto/Pto â—� Severe" exact="depression" post="can be seen in 2.4% of patients receiving Efvâ—�"/>
  <result pre="of patients receiving Efvâ—� Consider substituting for Efv if severe" exact="depression" post="develops Headache Azt, Efv,all integrase inhibitors Cs, Bdq â—�"/>
  <result pre="â—� Rule out more serious causes of headache, such as" exact="bacterial meningitis," post="cryptococcal meningitis, CNS toxoplasmosisâ—� Use of analgesics (ibuprofen, paracetamol)"/>
  <result pre="out more serious causes of headache, such as bacterial meningitis," exact="cryptococcal meningitis," post="CNS toxoplasmosisâ—� Use of analgesics (ibuprofen, paracetamol) and good"/>
  <result pre="of analgesics (ibuprofen, paracetamol) and good hydration may help.â—� Headache" exact="secondary" post="to Azt, Efv, and Cs is usually self-limited Nausea"/>
  <result pre="vomiting and abdominal pain may be a result of developing" exact="lactic acidosis" post="and/or hepatitis secondary to medications Abdominal pain All ART"/>
  <result pre="and abdominal pain may be a result of developing lactic" exact="acidosis" post="and/or hepatitis secondary to medications Abdominal pain All ART"/>
  <result pre="pain may be a result of developing lactic acidosis and/or" exact="hepatitis" post="secondary to medications Abdominal pain All ART treatments have"/>
  <result pre="may be a result of developing lactic acidosis and/or hepatitis" exact="secondary" post="to medications Abdominal pain All ART treatments have been"/>
  <result pre="of severe adverse drug reactions, such as pancreatitis, hepatitis, or" exact="lactic acidosis" post="Pancreatitis D4T, ddI, ddC Lzd â—� Avoid use of"/>
  <result pre="severe adverse drug reactions, such as pancreatitis, hepatitis, or lactic" exact="acidosis" post="Pancreatitis D4T, ddI, ddC Lzd â—� Avoid use of"/>
  <result pre="Also consider gallstones or alcohol as a potential cause of" exact="pancreatitis" post="Diarrhea All protease inhibitors, ddI (buffered formula), Rgv Eto/Pto,"/>
  <result pre="consider gallstones or alcohol as a potential cause of pancreatitis" exact="Diarrhea" post="All protease inhibitors, ddI (buffered formula), Rgv Eto/Pto, PAS,Ofx,"/>
  <result pre="inhibitors, ddI (buffered formula), Rgv Eto/Pto, PAS,Ofx, Lfx, Mfx â—�" exact="Diarrhea" post="is a common adverse drug reactionâ—� Also consider opportunistic"/>
  <result pre="â—� Diarrhea is a common adverse drug reactionâ—� Also consider" exact="opportunistic infections" post="as a cause of diarrhea, or Clostridium difficile (a"/>
  <result pre="Diarrhea is a common adverse drug reactionâ—� Also consider opportunistic" exact="infections" post="as a cause of diarrhea, or Clostridium difficile (a"/>
  <result pre="if the patient is receiving this medicationâ—� Also rule out" exact="viral" post="etiologies, such as cause of hepatitis (hepatitis A, B,"/>
  <result pre="medicationâ—� Also rule out viral etiologies, such as cause of" exact="hepatitis" post="(hepatitis A, B, C, and CMV) Skin rash Abc,"/>
  <result pre="T is contraindicated in HIV because of life-threatening rash Lactic" exact="acidosis" post="D4T, ddI, Azt, 3TC Lzd â—� If an agent"/>
  <result pre="D4T, ddI, Azt, 3TC Lzd â—� If an agent causes" exact="lactic acidosis," post="replace it with an agent less likely to cause"/>
  <result pre="acidosis, replace it with an agent less likely to cause" exact="lactic acidosis" post="Nephrotoxicity TDF Sm, Km,Am, Cm, Lfx â—� TDF may"/>
  <result pre="replace it with an agent less likely to cause lactic" exact="acidosis" post="Nephrotoxicity TDF Sm, Km,Am, Cm, Lfx â—� TDF may"/>
  <result pre="â—� TDF may cause renal injury with features characteristic of" exact="Fanconi syndrome," post="hypophosphatemia, hypouricemia, proteinuria, normoglycemic glycosuria, and in some cases"/>
  <result pre="syndrome, hypophosphatemia, hypouricemia, proteinuria, normoglycemic glycosuria, and in some cases" exact="acute" post="renal failureâ—� Use TDF with caution in patients receiving"/>
  <result pre="and electrolyte monitoring every 1 to 3 weeks is recommended" exact="Nephrolithiasis" post="Idv None â—� No overlapping toxicities regarding nephrolithiasis have"/>
  <result pre="is recommended Nephrolithiasis Idv None â—� No overlapping toxicities regarding" exact="nephrolithiasis" post="have been documented between ART and anti-TB medicationsâ—� Adequate"/>
  <result pre="been documented between ART and anti-TB medicationsâ—� Adequate hydration prevents" exact="nephrolithiasis" post="in patients taking Idvâ—� If nephrolithiasis develops while on"/>
  <result pre="medicationsâ—� Adequate hydration prevents nephrolithiasis in patients taking Idvâ—� If" exact="nephrolithiasis" post="develops while on Idv, substitute with another PI if"/>
  <result pre="PI if possible Electrolyte disturbances TDF Cm, Sm, Km,Am â—�" exact="Diarrhea" post="and/or vomiting can contribute to electrolyte disturbancesâ—� Even without"/>
  <result pre="have increased risk of both renal toxicity and electrolyte disturbances" exact="secondary" post="to aminoglycosides and Cm Bone-marrow suppression Azt Lzd, R,"/>
  <result pre="Consider adding folinic acid supplements, especially if receiving Tmp-Smx Optic" exact="neuritis" post="ddI E,Eto/Pto (rare) â—� Suspend agent responsible for optic"/>
  <result pre="Optic neuritis ddI E,Eto/Pto (rare) â—� Suspend agent responsible for" exact="optic neuritis" post="permanentlyâ—� Replace with an agent that does not cause"/>
  <result pre="neuritis ddI E,Eto/Pto (rare) â—� Suspend agent responsible for optic" exact="neuritis" post="permanentlyâ—� Replace with an agent that does not cause"/>
  <result pre="neuritis permanentlyâ—� Replace with an agent that does not cause" exact="optic neuritis" post="Hyperlipidemia PIs, Efv None â—� No overlapping toxicities regarding"/>
  <result pre="permanentlyâ—� Replace with an agent that does not cause optic" exact="neuritis" post="Hyperlipidemia PIs, Efv None â—� No overlapping toxicities regarding"/>
  <result pre="Replace with an agent that does not cause optic neuritis" exact="Hyperlipidemia" post="PIs, Efv None â—� No overlapping toxicities regarding hyperlipidemia"/>
  <result pre="neuritis Hyperlipidemia PIs, Efv None â—� No overlapping toxicities regarding" exact="hyperlipidemia" post="have been documented between ART and anti-TB medications Lipodystrophy"/>
  <result pre="regarding hyperlipidemia have been documented between ART and anti-TB medications" exact="Lipodystrophy" post="NRTIs (especially D4T and ddI) None â—� No overlapping"/>
  <result pre="(especially D4T and ddI) None â—� No overlapping toxicities regarding" exact="lipodystrophy" post="have been documented between ART and anti-TB medications Dysglycemia(disturbed"/>
  <result pre="insulin control in diabetics more difficult and can result in" exact="hypoglycemia" post="and poor glucose regulation Hypothyroidism D4T Eto/Pto, PAS â—�"/>
  <result pre="difficult and can result in hypoglycemia and poor glucose regulation" exact="Hypothyroidism" post="D4T Eto/Pto, PAS â—� There is potential for overlying"/>
  <result pre="overlying toxicity, but evidence is mixedâ—� Several studies show subclinical" exact="hypothyroidism" post="associated with ART, particularly d4Tâ—� PAS and Eto/Pto, especially"/>
  <result pre="d4Tâ—� PAS and Eto/Pto, especially in combination, can commonly cause" exact="hypothyroidism" post="Myopathyrhabdomyolysis Azt, Rgv E, Z â—� Clinical correlation to"/>
  <result pre="creatine phosphokinaseâ—� Thorough clinical evaluation to rule out HIV-associated myopathyâ—�" exact="Muscle" post="biopsy can be performedâ—� Azt-associated mitochondrial myopathy QT prolongation"/>
  <result pre="rule out HIV-associated myopathyâ—� Muscle biopsy can be performedâ—� Azt-associated" exact="mitochondrial myopathy" post="QT prolongation Efv, All PIs Lfx, Mfx, Cfz, Bdq,"/>
  <result pre="out HIV-associated myopathyâ—� Muscle biopsy can be performedâ—� Azt-associated mitochondrial" exact="myopathy" post="QT prolongation Efv, All PIs Lfx, Mfx, Cfz, Bdq,"/>
  <result pre="as the â€œthree Isâ€�: intensified case-finding, isoniazid preventive therapy, and" exact="infection" post="control. The Joint United Nations Programme on HIV/AIDS (UNAIDS)"/>
  <result pre="Isâ€�: intensified case-finding, isoniazid preventive therapy, and infection control. The" exact="Joint" post="United Nations Programme on HIV/AIDS (UNAIDS) has also collaborated"/>
  <result pre="therapy, and infection control. The Joint United Nations Programme on" exact="HIV/AIDS" post="(UNAIDS) has also collaborated with the WHO to reduce"/>
  <result pre="hit earlyâ€� has been implemented to reduce the burden of" exact="HIV infection." post="The United Nations aims to end AIDS epidemics by"/>
  <result pre="should be initiated on ART, 90% of which should demonstrate" exact="viral" post="suppression).75 The following activities are based on TB/HIV activities"/>
  <result pre="prevent attrition or loss to follow-up. Standard Protocols to Diagnose" exact="Pulmonary" post="and Extrapulmonary TB New protocols need to be devised,"/>
  <result pre="for enhancing the diagnosis and treatment of PLHIV with smear-negative" exact="pulmonary" post="and extrapulmonary TB. Mycobacterial cultures (conventional or liquid) of"/>
  <result pre="Africa have been able to scale up GeneXpert MTB/RIF in" exact="primary" post="health care.76 Nearly 500,200 PLHIV have been offered the"/>
  <result pre="and HIV epidemics. Figure 1 Algorithm for diagnosis of drug-resistant" exact="tuberculosis" post="in people living with HIV. Prompt Introduction of ART"/>
  <result pre="prompt initiation of ART in HIV-infected patients with M/XDR-TB. Other" exact="opportunistic infections" post="apart from TB, if present, should also be aggressively"/>
  <result pre="initiation of ART in HIV-infected patients with M/XDR-TB. Other opportunistic" exact="infections" post="apart from TB, if present, should also be aggressively"/>
  <result pre="Cotrimoxazole prevention therapy should be provided to all patients with" exact="HIV infection." post="No significant interaction has been observed with any second-line"/>
  <result pre="patients should be offered additional socioeconomic and nutritional support. Effective" exact="Infection" post="Control Infection-control measures should be implemented to reduce the"/>
  <result pre="measures should be implemented to reduce the risk of Mycobacterium" exact="tuberculosis" post="transmission in HIV-endemic settings. Infection-control measures recommended by the"/>
  <result pre="DR-TB patients should be targeted separately, due to emergence of" exact="primary" post="resistance, apart from management of DS-TB to break the"/>
  <result pre="with newer drugs to improve adherence, decentralized or patient-centric approaches," exact="infection" post="control, and preventive treatment for DR-TB contacts, have been"/>
  <result pre="children.89 That rate is almost similar to that reported among" exact="MDR-TB" post="patients in general, regardless of HIV status. Mortality was"/>
  <result pre="5.8%â€&quot;17.1%) in children.89 Mortality was higher for XDR-TB (82%) than" exact="MDR-TB" post="(67%) with HIV coinfection. Another study from sub-Saharan African"/>
  <result pre="than MDR-TB (67%) with HIV coinfection. Another study from sub-Saharan" exact="African" post="countries reported pooled cure and mortality rates of 34.9%"/>
  <result pre="pooled cure and mortality rates of 34.9% and 18.1%, respectively.32" exact="MDR-TB" post="and HIVâ€&quot;coinfected patients had more unfavorable outcomes than HIV-negative"/>
  <result pre="MDR-TB and HIVâ€&quot;coinfected patients had more unfavorable outcomes than HIV-negative" exact="MDR-TB" post="patients (RR 0.87, 95% CI 0.97â€&quot;0.96). However, the pooled"/>
  <result pre="the pooled cure rate from the European region is even" exact="lower" post="(16%).90 Factors responsible for the variable results are difference"/>
  <result pre="results are difference in populations affected, sample size, extent of" exact="disease" post="burden, and quality of treatment services offered. Shorter regimens"/>
  <result pre="services offered. Shorter regimens might show promising results, particularly in" exact="MDR-TB" post="patients with HIV coinfection, but current evidence is sparse"/>
  <result pre="study from Africa reported a high level of success among" exact="HIV-positive" post="patients with shorter regimens.91 Resistance to FQs, whether at"/>
  <result pre="high level of success among HIV-positive patients with shorter regimens.91" exact="Resistance" post="to FQs, whether at baseline or acquired, was responsible"/>
  <result pre="responsible for unfavorable outcomes. An important concern remains: whether an" exact="MDR-TB" post="regimen will work in all settings, particularly outside trial"/>
  <result pre="assess its efficacy. The factors responsible for unfavorable outcomes were" exact="atypical" post="clinical manifestations of TB and lack of rapid and"/>
  <result pre="with M/XDR-TB and HIV coinfection; additional comorbid illnesses, such as" exact="diabetes mellitus," post="anemia, renal or hepatic failure, and other opportunistic infections;"/>
  <result pre="as diabetes mellitus, anemia, renal or hepatic failure, and other" exact="opportunistic infections;" post="a higher pill burden resulting from the coadministration of"/>
  <result pre="immunosuppression (CD4 count &amp;lt;100 cells/cm3), unemployment, male sex, smoking, pregnancy," exact="drug abuse," post="coinfection with hepatitis B or C, and a higher"/>
  <result pre="cells/cm3), unemployment, male sex, smoking, pregnancy, drug abuse, coinfection with" exact="hepatitis" post="B or C, and a higher degree of drug"/>
  <result pre="Outbreaks should be prevented to reduce the impact on mortality." exact="Tuberculosis" post="Immunoreconstitution Inflammatory Syndrome TB-IRIS is an unusually exaggerated immunoresponse"/>
  <result pre="be prevented to reduce the impact on mortality. Tuberculosis Immunoreconstitution" exact="Inflammatory" post="Syndrome TB-IRIS is an unusually exaggerated immunoresponse against viable"/>
  <result pre="prevented to reduce the impact on mortality. Tuberculosis Immunoreconstitution Inflammatory" exact="Syndrome" post="TB-IRIS is an unusually exaggerated immunoresponse against viable or"/>
  <result pre="is an unusually exaggerated immunoresponse against viable or dead M." exact="tuberculosis" post="antigens, and occurs frequently in HIV-infected patients compared with"/>
  <result pre="and observed particularly when the site of involvement is the" exact="central nervous system." post="IRIS has been observed for other opportunistic infections or"/>
  <result pre="the central nervous system. IRIS has been observed for other" exact="opportunistic infections" post="or HIV-associated illnesses apart from TB. A retrospective meta-analysis"/>
  <result pre="central nervous system. IRIS has been observed for other opportunistic" exact="infections" post="or HIV-associated illnesses apart from TB. A retrospective meta-analysis"/>
  <result pre="is either appearance of new lesions or deterioration/recurrence of preexisting" exact="pulmonary" post="or extrapulmonary tubercular lesions in patients undergoing anti-TB treatment."/>
  <result pre="and is more common with CD4 count &amp;lt;50 cells/cm3.94,95 This" exact="syndrome" post="can present as a paradoxical worsening of the patientâ€™s"/>
  <result pre="clinical status, often due to a previously subclinical and unrecognized" exact="opportunistic infection." post="Clinical features include hastening of symptoms, deteriorating pulmonary lesions,"/>
  <result pre="unrecognized opportunistic infection. Clinical features include hastening of symptoms, deteriorating" exact="pulmonary" post="lesions, or exacerbation of inflammation, such as enlarging lymphadenopathy"/>
  <result pre="lesions, or exacerbation of inflammation, such as enlarging lymphadenopathy or" exact="pleural" post="effusion, at the sites of involvement. The unmasking form"/>
  <result pre="form is an inflammatory manifestation of an apparently asymptomatic subclinical" exact="infection" post="occurring after initiation of ART, resulting in clinical worsening."/>
  <result pre="initiation of ART, resulting in clinical worsening. Patients with advanced" exact="disease" post="may show clinical deterioration caused by other reasons. It"/>
  <result pre="include superimposed infections, treatment failure, and relapse and progression of" exact="disease" post="due to drug resistance. Strict criteria should be defined"/>
  <result pre="anti-TB therapy. Nonsteroidal anti-inflammatory drugs can be used in mild" exact="disease" post="and corticosteroids in moderateâ€&quot;severe disease. Interruption of ART is"/>
  <result pre="is usually required in a few cases. Chemoprophylaxis of Drug-Resistant" exact="Tuberculosis" post="PLHIV are vulnerable to infection with TB bacillus, including"/>
  <result pre="few cases. Chemoprophylaxis of Drug-Resistant Tuberculosis PLHIV are vulnerable to" exact="infection" post="with TB bacillus, including DR ones. The annual risk"/>
  <result pre="bacillus, including DR ones. The annual risk of developing TB" exact="infection" post="in the HIV-infected population is ten times that of"/>
  <result pre="uninfected.98,99 Screening is required for ruling out not only active" exact="infection" post="but also latent infection. Chemoprophylaxis is indicated if the"/>
  <result pre="but also latent infection. Chemoprophylaxis is indicated if the latent" exact="infection" post="is detected by immunologic testing, such as tuberculin skin"/>
  <result pre="chemoprophylaxis has been reported to reduce the risk of TB" exact="infection" post="by 35%, with larger benefit in the skin testâ€&quot;positive"/>
  <result pre="has also been observed to reduce the risk of HIV" exact="disease" post="progression by 31%. Therefore, chemoprophylaxis is an important preventive"/>
  <result pre="is an important preventive therapy in DS-TB and HIV coinfection." exact="Limited" post="evidence is available regarding the role of chemoprophylaxis in"/>
  <result pre="is available regarding the role of chemoprophylaxis in preventing active" exact="disease" post="among people with or without HIV infection havin contacts"/>
  <result pre="chemoprophylaxis in preventing active disease among people with or without" exact="HIV infection" post="havin contacts with M/XDR-TB patients.103,104 People in whom latent"/>
  <result pre="in preventing active disease among people with or without HIV" exact="infection" post="havin contacts with M/XDR-TB patients.103,104 People in whom latent"/>
  <result pre="infection havin contacts with M/XDR-TB patients.103,104 People in whom latent" exact="infection" post="is diagnosed are often infected with the same strain"/>
  <result pre="progression of disease. If the contact is symptomatic, presumptive TB" exact="infection" post="should be suspected and investigated further with the CBNAAT"/>
  <result pre="index case is recommended in cases of development of active" exact="disease" post="till DST results are collected. There is a lack"/>
  <result pre="index case of DR-TB. The reduction of risk of developing" exact="infection" post="has been reported to be 37%â€&quot;90%.100,101,104 These regimens are"/>
  <result pre="(PHOENIXMDR-TB trial).78 National programs should emphasize chemoprophylaxis in preventing latent" exact="infection" post="among HIV-endemic areas where the probability of DR-TB coinfection"/>
  <result pre="to prove the efficacy of chemoprophylaxis in the prevention of" exact="infection" post="in PLHIV with contacts with M/XDR-TB. Infection Control Infection"/>
  <result pre="the prevention of infection in PLHIV with contacts with M/XDR-TB." exact="Infection" post="Control Infection control is one of the essential components"/>
  <result pre="of infection in PLHIV with contacts with M/XDR-TB. Infection Control" exact="Infection" post="control is one of the essential components of management"/>
  <result pre="with or without HIV coinfection. It restricts the transmission of" exact="infection" post="from patients to high-risk groups, especially health-care workers. There"/>
  <result pre="and HIV are responsible for nosocomial transmission. These practices enhance" exact="infection" post="epidemics or outbreaks, particularly in HIV-endemic settings. Implementation of"/>
  <result pre="health centers or hospitals significantly reduces nosocomial transmission.106 Interventions for" exact="infection" post="control should be adopted at three levels: administrative, environmental/engineering,"/>
  <result pre="should be adopted at three levels: administrative, environmental/engineering, and personal" exact="respiratory" post="protection. Administrative controls include patient screening, cough hygiene, segregation"/>
  <result pre="for ventilation, which are effective but complex and costly. Personal" exact="respiratory" post="protection including N95 particulate respirators, is indicated when the"/>
  <result pre="larger scale. Home-based measures, such as separate living quarters, personal" exact="respiratory" post="protection for visitors, and adequate ventilation, have also been"/>
  <result pre="References 1.collab: World Health Organization. WHO consolidated guidelines on drug-resistant" exact="tuberculosis" post="treatment. Geneva: WHO; 2019(WHO/CDS/TB/2019.7); Available from:https://apps.who.int&amp;gt;iris&amp;gt;bitstream&amp;gt;handle&amp;gt;9789241550529-eng. Accessed 615, 2019."/>
  <result pre="from:https://apps.who.int&amp;gt;iris&amp;gt;bitstream&amp;gt;handle&amp;gt;9789241550529-eng. Accessed 615, 2019. 2.DyeC, BassiliA, BierrenbachAL, et al. Measuring" exact="tuberculosis" post="burden, trends and the impact of control programmes. Lancet"/>
  <result pre="Lancet Infect Dis. 2008;8(4):233â€&quot;243. doi:10.1016/S1473-3099(07)70291-818201929 3.WellsCD, CegielskiJP, NelsonLJ, et al." exact="HIV infection" post="and multi-drug resistant tuberculosis: the perfect storm. J Infect"/>
  <result pre="Infect Dis. 2008;8(4):233â€&quot;243. doi:10.1016/S1473-3099(07)70291-818201929 3.WellsCD, CegielskiJP, NelsonLJ, et al. HIV" exact="infection" post="and multi-drug resistant tuberculosis: the perfect storm. J Infect"/>
  <result pre="Dis. 2007;196(Suppl 1):S86â€&quot;S107. doi:10.1086/51866517624830 4.DubrovinaI, MiskinisK, GilksC, et al. Drug-resistant" exact="tuberculosis" post="and HIV in Ukraine: a threatening convergence of two"/>
  <result pre="J Tuberc Lung Dis. 2008;12(7):756â€&quot;762.18544200 5.collab: World Health Organization. Global" exact="tuberculosis" post="report 2019. Geneva: WHO; 2019(WHO/CDS/TB/2019.15)Available from:https://www.who.int/tb/publications/global_report/en/. Accessed 2810 2019."/>
  <result pre="2019(WHO/CDS/TB/2019.15)Available from:https://www.who.int/tb/publications/global_report/en/. Accessed 2810 2019. 6.SuchindranS, BrouwerES, Van RieA. Is" exact="HIV infection" post="a risk factor for multi-drug-resistant tuberculosis? A systematic review."/>
  <result pre="from:https://www.who.int/tb/publications/global_report/en/. Accessed 2810 2019. 6.SuchindranS, BrouwerES, Van RieA. Is HIV" exact="infection" post="a risk factor for multi-drug-resistant tuberculosis? A systematic review."/>
  <result pre="epidemics. ERJ. 2014;44(1):251â€&quot;254. doi:10.1183/09031936.00205413 9.MesfinYM, HailemariamD, BiadglignS, KibretKT. Association between" exact="HIV/AIDS" post="and multi-drug resistance tuberculosis: a systematic review and meta-analysis."/>
  <result pre="al. Evaluation of Gene Xpert for routine diagnosis of HIV-associated" exact="tuberculosis" post="in Nigeria: a prospective cohort study. BMC Pulm Med."/>
  <result pre="doi:10.1186/s12890-017-0430-628558662 11.MageeMJ, BlumbergHM, BrozD, et al. Prevalence of drug resistant" exact="tuberculosis" post="among patients at high-risk for HIV attending outpatient clinics"/>
  <result pre="Health. 2012;43(2):354â€&quot;363.23082587 12.DagnraAY, MlagaKD, AdjohK, KadangaE, DisseK, AdekambiT. Prevalence of" exact="multidrug-resistant tuberculosis" post="cases among HIV-positive and HIV-negative patients eligible for retreatment"/>
  <result pre="2012;43(2):354â€&quot;363.23082587 12.DagnraAY, MlagaKD, AdjohK, KadangaE, DisseK, AdekambiT. Prevalence of multidrug-resistant" exact="tuberculosis" post="cases among HIV-positive and HIV-negative patients eligible for retreatment"/>
  <result pre="AdjohK, KadangaE, DisseK, AdekambiT. Prevalence of multidrug-resistant tuberculosis cases among" exact="HIV-positive" post="and HIV-negative patients eligible for retreatment regimen in Togo"/>
  <result pre="2015;10(2):e0116721. doi:10.1371/journal.pone.011672125658091 14.LawnSD, BrooksSV, KranzerK, et al. Screening for HIV-associated" exact="tuberculosis" post="and rifampicin resistance before antiretroviral therapy using the xpert"/>
  <result pre="GhanekarC, GaikwadS, SaneS, PujariS. High prevalence of multi drug resistant" exact="tuberculosis" post="in people living with HIV in Western Indias. BMC"/>
  <result pre="2019;19:391.31068153 16.ChumHJ, Oâ€™BrienRJ, ChondeTM, GrafP, RiederHL. An epidemiological study of" exact="tuberculosis" post="and HIV infection in Tanzania, 1991â€&quot;1993. AIDS. 1996;10(3):299â€&quot;309. doi:10.1097/00002030-199603000-000098882670"/>
  <result pre="Oâ€™BrienRJ, ChondeTM, GrafP, RiederHL. An epidemiological study of tuberculosis and" exact="HIV infection" post="in Tanzania, 1991â€&quot;1993. AIDS. 1996;10(3):299â€&quot;309. doi:10.1097/00002030-199603000-000098882670 17.KenyonTA, MwasekagaMJ, HuebnerR,"/>
  <result pre="ChondeTM, GrafP, RiederHL. An epidemiological study of tuberculosis and HIV" exact="infection" post="in Tanzania, 1991â€&quot;1993. AIDS. 1996;10(3):299â€&quot;309. doi:10.1097/00002030-199603000-000098882670 17.KenyonTA, MwasekagaMJ, HuebnerR,"/>
  <result pre="RumishaD, BinkinN. Low levels of drug resistance amidst rapidly increasing" exact="tuberculosis" post="and human immunodeficiency virus co-epidemics in Botswana. Int J"/>
  <result pre="levels of drug resistance amidst rapidly increasing tuberculosis and human" exact="immunodeficiency" post="virus co-epidemics in Botswana. Int J Tuberc Lung Dis."/>
  <result pre="Lung Dis. 1999;3(1):4â€&quot;11.10094163 18.ChurchyardGJ, CorbettEL, KlinschmidtI, MulderD, De CockKM. Drug-resistant" exact="tuberculosis" post="in South African gold miners: incidence and associated factors."/>
  <result pre="18.ChurchyardGJ, CorbettEL, KlinschmidtI, MulderD, De CockKM. Drug-resistant tuberculosis in South" exact="African" post="gold miners: incidence and associated factors. Int J Tuberc"/>
  <result pre="PerdiagaoP, et al. Characteristics of drug resistance and HIV among" exact="tuberculosis" post="patients in Mozambique. Int J Tuberc Lung Dis. 2001;5(10):894â€&quot;902.11605881"/>
  <result pre="Dis. 2001;5(10):894â€&quot;902.11605881 20.CamposPE, SuarezPG, SanchezJ, et al. Multi-drug resistant Mycobacterium" exact="tuberculosis" post="in HIV-infected persons, Peru. Emerg Infect Dis. 2003;9(12):1571â€&quot;1578. doi:10.3201/eid0912.02073114720398"/>
  <result pre="2001;5(10):887â€&quot;893.11605880 22.QuyHT, BuuTN, CobelensFGJ, et al. Drug resistance among smear-positive" exact="tuberculosis" post="patients in Ho Chi Minh City, Vietnam. Int J"/>
  <result pre="2006;43(7):841â€&quot;847. doi:10.1086/cid.2006.43.issue-716941364 24.EdlinBR, TokarsJI, GriecoMH, et al. An outbreak of" exact="multidrug-resistant tuberculosis" post="among hospitalized patients with the acquired immunodeficiency syndrome. N"/>
  <result pre="doi:10.1086/cid.2006.43.issue-716941364 24.EdlinBR, TokarsJI, GriecoMH, et al. An outbreak of multidrug-resistant" exact="tuberculosis" post="among hospitalized patients with the acquired immunodeficiency syndrome. N"/>
  <result pre="An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the" exact="acquired immunodeficiency syndrome." post="N Engl J Med. 1992;326(23):1514â€&quot;1521. doi:10.1056/NEJM1992060432623021304721 25.MoroML, GoriA, ErranteI,"/>
  <result pre="outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired" exact="immunodeficiency" post="syndrome. N Engl J Med. 1992;326(23):1514â€&quot;1521. doi:10.1056/NEJM1992060432623021304721 25.MoroML, GoriA,"/>
  <result pre="25.MoroML, GoriA, ErranteI, et al. An outbreak of multidrug resistant" exact="tuberculosis" post="involving HIV infected patients of two hospitals in Milan,"/>
  <result pre="AIDS. 1998;12(9):1095â€&quot;1102. doi:10.1097/00002030-199809000-000189662207 26.GandhiNR, MollA, SturmAW, et al. Extensively drug-resistant" exact="tuberculosis" post="as a cause of death in patients co-infected with"/>
  <result pre="tuberculosis as a cause of death in patients co-infected with" exact="tuberculosis" post="and HIV in a rural area of South Africa."/>
  <result pre="ShahNS, AndrewsJR, et al. HIV co-infection in multidrug-and extensively drug-resistant" exact="tuberculosis" post="results in high early mortality. Am J Respir Crit"/>
  <result pre="et al. Anti-tuberculosis drug resistance and anonymous HIV surveillance in" exact="tuberculosis" post="patients in Botswana, 2002. Lancet. 2005;366(9484):488â€&quot;490. doi:10.1016/S0140-6736(05)67062-616084258 32.ChemED, Van"/>
  <result pre="32.ChemED, Van HoutMC, HopeV. Treatment outcomes and anti-retroviral uptake in" exact="multidrug-resistant tuberculosis" post="and HIV co-infected patients in Sub-Saharan Africa: a systematic"/>
  <result pre="Van HoutMC, HopeV. Treatment outcomes and anti-retroviral uptake in multidrug-resistant" exact="tuberculosis" post="and HIV co-infected patients in Sub-Saharan Africa: a systematic"/>
  <result pre="33.FriedenTR, SterlingT, Pablos-MendezA, KilburnJO, CauthenGM, DooleySW. The emergence of drug-resistant" exact="tuberculosis" post="in New York City. N Engl J Med. 1993;328(8):521â€&quot;526."/>
  <result pre="doi:10.1056/NEJM1993022532808018381207 34.CoronadoVG, Beck-SagueCM, HuttonMD, et al. Transmission of multidrug-resistant Mycobacterium" exact="tuberculosis" post="among persons with human immunodeficiency virus infection in an"/>
  <result pre="al. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human" exact="immunodeficiency" post="virus infection in an urban hospital: epidemiologic and restriction"/>
  <result pre="Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency" exact="virus infection" post="in an urban hospital: epidemiologic and restriction fragment length"/>
  <result pre="of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus" exact="infection" post="in an urban hospital: epidemiologic and restriction fragment length"/>
  <result pre="J Infect Dis. 1993;168(4):1052â€&quot;1055. doi:10.1093/infdis/168.4.10528104226 35.BusilloC, LessnauK-D, SanjanaV. Multidrug-resistant Mycobacterium" exact="tuberculosis" post="in patients with human immunodeficiency virus infection. Chest. 1992;102(3):797â€&quot;801."/>
  <result pre="35.BusilloC, LessnauK-D, SanjanaV. Multidrug-resistant Mycobacterium tuberculosis in patients with human" exact="immunodeficiency" post="virus infection. Chest. 1992;102(3):797â€&quot;801. doi:10.1378/chest.102.3.7971516405 36.ShaferRW, SmallPM, LarkinC, et"/>
  <result pre="LessnauK-D, SanjanaV. Multidrug-resistant Mycobacterium tuberculosis in patients with human immunodeficiency" exact="virus infection." post="Chest. 1992;102(3):797â€&quot;801. doi:10.1378/chest.102.3.7971516405 36.ShaferRW, SmallPM, LarkinC, et al. Temporal"/>
  <result pre="al. Temporal trends and transmission patterns during the emergence of" exact="multidrug-resistant tuberculosis" post="in New York City: a molecular epidemiologic assessment. J"/>
  <result pre="Temporal trends and transmission patterns during the emergence of multidrug-resistant" exact="tuberculosis" post="in New York City: a molecular epidemiologic assessment. J"/>
  <result pre="Impact of HIV co-infection on the evolution and transmission of" exact="multidrug-resistant tuberculosis." post="Elife. 2016;5:e16644. doi:10.7554/eLife.1664427502557 38.RakeshPS, BalakrishnanS, JayasankarS, AsokanRV. TB management"/>
  <result pre="doi:10.1016/j.ijtb.2016.09.00927998498 39.IsaakidisP, DasM, KumarAMV, et al. Alarming levels of drug-resistant" exact="tuberculosis" post="in HIV-infected patients in Metropolitan Mumbai, India. PLoS One."/>
  <result pre="41.ShahNS, AuldSC, BrustJC, et al. Transmission of extensively drug resistant" exact="tuberculosis" post="in South Africa. N Engl J Med. 2017;376(3):243â€&quot;253. doi:10.1056/NEJMoa160454428099825"/>
  <result pre="42.CohenKA, AbeelT, Manson McGuireA, et al. Evolution of extensively drug-resistant" exact="tuberculosis" post="over four decades: whole genome sequencing and dating analysis"/>
  <result pre="four decades: whole genome sequencing and dating analysis of mycobacterium" exact="tuberculosis" post="isolates from KwaZulu-Natal. PLoS Med. 2015;12(9):e1001880. doi:10.1371/journal.pmed.100188026418737 43.KimerlingME, SlavuckijA,"/>
  <result pre="2015;12(9):e1001880. doi:10.1371/journal.pmed.100188026418737 43.KimerlingME, SlavuckijA, ChaversS, et al. The risk of" exact="MDR-TB" post="and poly-resistant tuberculosis among the civilian population of Tomsk"/>
  <result pre="SlavuckijA, ChaversS, et al. The risk of MDR-TB and poly-resistant" exact="tuberculosis" post="among the civilian population of Tomsk city, Siberia, 1999."/>
  <result pre="44.ZhaoM, LiX, XuP, et al. Transmission of MDR and XDR" exact="tuberculosis" post="in Shanghai, China. PLoS One. 2009;4(2):e4370. doi:10.1371/journal.pone.000437019190774 45.CainKP, McCarthyKD,"/>
  <result pre="2009;4(2):e4370. doi:10.1371/journal.pone.000437019190774 45.CainKP, McCarthyKD, HeiligCM, et al. An algorithm for" exact="tuberculosis" post="screening and diagnosis in people with HIV. N Engl"/>
  <result pre="2011;24(2):351â€&quot;376. doi:10.1128/CMR.00042-1021482729 47.ParsonsLM, SomoskÃ¶viA, GutierrezC, et al. Laboratory diagnosis of" exact="tuberculosis" post="in resource-poor countries: challenges and opportunities. Clin Microbiol Rev."/>
  <result pre="doi:10.1128/CMR.00059-1021482728 48.collab: WHO. Improving the diagnosis and treatment of smear-negative" exact="pulmonary" post="and extra-pulmonary tuberculosis among adults and adolescents: recommendations for"/>
  <result pre="Improving the diagnosis and treatment of smear-negative pulmonary and extra-pulmonary" exact="tuberculosis" post="among adults and adolescents: recommendations for HIV-prevalent and resource-constrained"/>
  <result pre="nucleic acid amplification technology for rapid and simultaneous detection of" exact="tuberculosis" post="and rifampicin resistance: xpert MTB/RIF assay for the diagnosis"/>
  <result pre="and rifampicin resistance: xpert MTB/RIF assay for the diagnosis of" exact="pulmonary" post="and extra-pulmonary TB in adults and children. Geneva: WHO;"/>
  <result pre="AllandD, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium" exact="tuberculosis" post="and rifampicin resistance: a prospective multi-centre diagnostic accuracy study."/>
  <result pre="prognostic value of determine TB-LAM for routine diagnostic testing for" exact="tuberculosis" post="in HIV-infected patients requiring acute hospital admission in South"/>
  <result pre="for routine diagnostic testing for tuberculosis in HIV-infected patients requiring" exact="acute" post="hospital admission in South Africa: a prospective cohort. BMC"/>
  <result pre="54.MaiTQ, Van AnhNT, HienNT, et al. Drug resistance and Mycobacterium" exact="tuberculosis" post="strain diversity in TB/HIV co-infected patients in Ho Chi"/>
  <result pre="Antimicrob Resist. 2017;10:154â€&quot;160. doi:10.1016/j.jgar.2017.07.00328743648 55.MaiTQ, MartinezE, MenonR, et al. Mycobacterium" exact="tuberculosis" post="drug resistance and transmission among human immunodeficiency virus-infected patients"/>
  <result pre="et al. Mycobacterium tuberculosis drug resistance and transmission among human" exact="immunodeficiency" post="virus-infected patients in Ho Chi Minh City, vietnam. Am"/>
  <result pre="DaftaryA, et al. Antiretroviral switching and bedaquiline treatment of drug-resistant" exact="tuberculosis" post="HIV co-infection. Lancet HIV. 2019;6(3):e201â€&quot;e204. doi:10.1016/S2352-3018(19)30035-930846058 65.MallikaarjunS, WellsC, PetersenC,"/>
  <result pre="2016;60(10):5976â€&quot;5985. doi:10.1128/AAC.00509-1627458223 66.HoffmannCJ, ChristopherJ, CharalambousS, et al. Hepatotoxicity in an" exact="African" post="antiretroviral therapy cohort: the effect of tuberculosis and hepatitis"/>
  <result pre="Hepatotoxicity in an African antiretroviral therapy cohort: the effect of" exact="tuberculosis" post="and hepatitis B. AIDS. 2007;21(10):1301â€&quot;1308. doi:10.1097/QAD.0b013e32814e6b0817545706 67.DeanGL, EdwardsSG, IvesNJ,"/>
  <result pre="an African antiretroviral therapy cohort: the effect of tuberculosis and" exact="hepatitis" post="B. AIDS. 2007;21(10):1301â€&quot;1308. doi:10.1097/QAD.0b013e32814e6b0817545706 67.DeanGL, EdwardsSG, IvesNJ, et al."/>
  <result pre="AIDS. 2007;21(10):1301â€&quot;1308. doi:10.1097/QAD.0b013e32814e6b0817545706 67.DeanGL, EdwardsSG, IvesNJ, et al. Treatment of" exact="tuberculosis" post="in HIV-infected persons in the era of highly active"/>
  <result pre="review and meta-analysis. Am J Ther. 2016;23:e521â€&quot;30. doi:10.1097/01.mjt.0000433951.09030.5a24284652 71.Dia-JeanetteT. Mycobacterial" exact="Disease" post="in HIV positive patients. J Pharm Practice. 2006;19(1):10â€&quot;16. doi:10.1177/0897190005284100"/>
  <result pre="al. Delays and loss to follow-up before treatment of drug-resistant" exact="tuberculosis" post="following implementation of Xpert MTB/RIF in South Africa: a"/>
  <result pre="Tuberc Lung Dis. 2019;23(5):535â€&quot;546. doi:10.5588/ijtld.18.021731097060 79.JonesJL, HansonDL, DworkinMS, DeCockKM. HIV-associated" exact="tuberculosis" post="in the era of highly active antiretroviral therapy. The"/>
  <result pre="of highly active antiretroviral therapy. The Adult/Adolescent spectrum of HIV" exact="disease" post="group. Int J Tuberc Lung Dis. 2000;4(11):1026â€&quot;1031.11092714 80.Waisman JL,"/>
  <result pre="JLG, Francos JL, Negroni R. [Mejor pronÃ³stico en pacientes con" exact="tuberculosis" post="multirresistente relacionados con el VIH/SIDA tratados con terapia antirretroviral"/>
  <result pre="et al. Antiretroviral Therapy Cohort Collaboration (ART-CC). Cause-specific mortality in" exact="HIV-positive" post="patients who survived ten years after starting antiretroviral therapy."/>
  <result pre="BoydR, et al. High treatment success rates among HIV infected" exact="multidrug-resistant tuberculosis" post="patients after expansion of antiretroviral therapy in Botswana, 2006â€&quot;2013."/>
  <result pre="et al. High treatment success rates among HIV infected multidrug-resistant" exact="tuberculosis" post="patients after expansion of antiretroviral therapy in Botswana, 2006â€&quot;2013."/>
  <result pre="Syndr. 2017;74(1):65â€&quot;71. doi:10.1097/QAI.000000000000116927552155 84.AhujaSD, AshkinD, AvendanoM, et al. Multidrug resistant" exact="pulmonary" post="tuberculosis treatment regimens and patient outcomes: an individual patient"/>
  <result pre="2017;74(1):65â€&quot;71. doi:10.1097/QAI.000000000000116927552155 84.AhujaSD, AshkinD, AvendanoM, et al. Multidrug resistant pulmonary" exact="tuberculosis" post="treatment regimens and patient outcomes: an individual patient data"/>
  <result pre="PadayatchiN. High treatment failure and default rates for patients with" exact="multidrug-resistant tuberculosis" post="in KwaZulu-Natal, South Africa, 2000â€&quot;2003. Int J Tuberc Lung"/>
  <result pre="High treatment failure and default rates for patients with multidrug-resistant" exact="tuberculosis" post="in KwaZulu-Natal, South Africa, 2000â€&quot;2003. Int J Tuberc Lung"/>
  <result pre="al. Time to ART initiation among patients treated for rifampicin-resistant" exact="tuberculosis" post="in Khayelitsha, South Africa: impact on mortality and treatment"/>
  <result pre="87.Oâ€™DonnellMR, PadayatchiN, KvasnovskyC, WernerL, MasterI, HorsburghCRJr.Treatment outcomes for extensively drug-resistant" exact="tuberculosis" post="and HIV co-infection. Emerg Infect Dis. 2013;19(3):416â€&quot;424. doi:10.3201/eid1903.12099823622055 88.CarlucciJG,"/>
  <result pre="Emerg Infect Dis. 2013;19(3):416â€&quot;424. doi:10.3201/eid1903.12099823622055 88.CarlucciJG, BlevinsPM, KippAM, et al." exact="Tuberculosis" post="treatment outcomes among HIV/TB Co-infected Children in the International"/>
  <result pre="CasasEC, DasM, TseretopoulouX, NtzaniEE, FordN. Treatment outcomes for HIV and" exact="MDR-TB" post="co-infected adults and children: systematic review and meta-analysis. Int"/>
  <result pre="2015;19(8):969â€&quot;978. doi:10.5588/ijtld.15.012326162364 90.Magis-EscurraC, GÃ¼ntherG, LangeC, et al. Treatment outcomes of" exact="MDR-TB" post="and HIV co-infection in Europe. Eur Respir J. 2017;49:1602363."/>
  <result pre="doi:10.1183/13993003.02363-201628596434 91.TrebucqA, SchwoebelV, KashongweZ, et al. Treatment outcome with a" exact="short" post="multidrug-resistant tuberculosis regimen in nine African countries. Int J"/>
  <result pre="91.TrebucqA, SchwoebelV, KashongweZ, et al. Treatment outcome with a short" exact="multidrug-resistant tuberculosis" post="regimen in nine African countries. Int J Tuberc Lung"/>
  <result pre="SchwoebelV, KashongweZ, et al. Treatment outcome with a short multidrug-resistant" exact="tuberculosis" post="regimen in nine African countries. Int J Tuberc Lung"/>
  <result pre="Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine" exact="African" post="countries. Int J Tuberc Lung Dis. 2018;22(1):17â€&quot;25. doi:10.5588/ijtld.17.049829149917 92.GandhiNR,"/>
  <result pre="Dis. 2012;16(1):90â€&quot;97. doi:10.5588/ijtld.11.015322236852 93.AzeezA, NdegeJ, MutambayiR. Associated factors with unsuccessful" exact="tuberculosis" post="treatment outcomes among tuberculosis/HIV co-infected patients with drug-resistant tuberculosis."/>
  <result pre="Mycobacteriol. 2018;7(4):347â€&quot;354. doi:10.4103/ijmy.ijmy_140_1830531033 94.NaritaM, AshkinD, HollenderES, PitchenikAE. Paradoxical worsening of" exact="tuberculosis" post="following antiretroviral therapy in patients with AIDS. Am J"/>
  <result pre="2007;21(3):335â€&quot;341. doi:10.1097/QAD.0b013e328011efac17255740 96.NavasE, MartÃ­n-DÃ¡vilaP, MorenoL, et al. Paradoxical reactions of" exact="tuberculosis" post="in patients with the acquired immunodeficiency syndrome who are"/>
  <result pre="et al. Paradoxical reactions of tuberculosis in patients with the" exact="acquired immunodeficiency syndrome" post="who are treated with highly active antiretroviral therapy. Arch"/>
  <result pre="al. Paradoxical reactions of tuberculosis in patients with the acquired" exact="immunodeficiency" post="syndrome who are treated with highly active antiretroviral therapy."/>
  <result pre="Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency" exact="syndrome" post="who are treated with highly active antiretroviral therapy. Arch"/>
  <result pre="2002;162(1):97â€&quot;99. doi:10.1001/archinte.162.1.9711784229 97.MullerM, WandelS, ColebundersR, et al. Immune re-constitution inflammatory" exact="syndrome" post="in patients starting antiretroviral therapy for HIV infection: a"/>
  <result pre="Infect Dis. 2010;10(4):251â€&quot;261. doi:10.1016/S1473-3099(10)70026-820334848 98.HorsburghCRJr.Priorities for the treatment of latent" exact="tuberculosis" post="infection in the United States. N Engl J Med."/>
  <result pre="Dis. 2010;10(4):251â€&quot;261. doi:10.1016/S1473-3099(10)70026-820334848 98.HorsburghCRJr.Priorities for the treatment of latent tuberculosis" exact="infection" post="in the United States. N Engl J Med. 2004;350(20):2060â€&quot;2067."/>
  <result pre="2004;350(20):2060â€&quot;2067. doi:10.1056/NEJMsa03166715141044 99.DurovniB, SaraceniV, MoultonLH, et al. Effect of improved" exact="tuberculosis" post="screening and isoniazid preventive therapy on incidence of tuberculosis"/>
  <result pre="improved tuberculosis screening and isoniazid preventive therapy on incidence of" exact="tuberculosis" post="and death in patients with HIV in clinics in"/>
  <result pre="MourikMS, DebrayTP, BontenMJ. Isoniazid prophylactic therapy for the prevention of" exact="tuberculosis" post="in HIV infected adults: a systematic review and meta-analysis"/>
  <result pre="One. 2015;10(11):e0142290. doi:10.1371/journal.pone.014229026551023 101.FraserA, PaulM, AttamnaA, LeiboviciL. Drugs for preventing" exact="tuberculosis" post="in people at risk of multiple drug- resistant pulmonary"/>
  <result pre="preventing tuberculosis in people at risk of multiple drug- resistant" exact="pulmonary" post="tuberculosis. Cochrane Database Syst Rev. 2006;19(2):CD005435. 102.MarksSM, MaseSR, MorrisSB."/>
  <result pre="MorrisSB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent" exact="tuberculosis" post="to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis."/>
  <result pre="cost-effectiveness of treatment of latent tuberculosis to reduce progression to" exact="multidrug-resistant tuberculosis." post="Clin Infect Dis. 2017;64(12):1670â€&quot;1677. doi:10.1093/cid/cix20828329197 103.FoxG, DoblerC, MaraisB, DenholmJ."/>
  <result pre="2017;64(12):1670â€&quot;1677. doi:10.1093/cid/cix20828329197 103.FoxG, DoblerC, MaraisB, DenholmJ. Preventive therapy for latent" exact="tuberculosis" post="infectionâ€&quot;the promise and the challenges. Int J Infec Dis."/>
  <result pre="Tuberc Res Treat. 2018;3905890:1â€&quot;8. doi:10.1155/2018/3905890 105.collab: World Health Organization. Latent" exact="tuberculosis" post="infection: updated and consolidated guidelines for programmatic management. Geneva:"/>
  <result pre="PoolmanEM, et al. Prevention of nosocomial transmission of extensively drug-resistant" exact="tuberculosis" post="in rural South African district hospitals: an epidemiological modelling"/>
  <result pre="of nosocomial transmission of extensively drug-resistant tuberculosis in rural South" exact="African" post="district hospitals: an epidemiological modelling study. Lancet. 2007;370(9597):1500â€&quot;1507. doi:10.1016/S0140-6736(07)61636-517964351"/>
  <result pre="doi:10.1016/S0140-6736(07)61636-517964351 107.ShinS, FurinJ, BayonaJ, MateK, KimJY, FarmerP. Community-based treatment of" exact="multidrug-resistant tuberculosis" post="in Lima, Peru: 7 years of experience. Soc Sci"/>
  <result pre="107.ShinS, FurinJ, BayonaJ, MateK, KimJY, FarmerP. Community-based treatment of multidrug-resistant" exact="tuberculosis" post="in Lima, Peru: 7 years of experience. Soc Sci"/>
 </snippets>
</snippetsTree>
